{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:20:18Z","timestamp":1784647218488,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00108-022-01286-z","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T16:05:32Z","timestamp":1647273932000},"page":"798-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Update zur diastolisch bedingten Herzinsuffizienz","Update on diastolic heart failure"],"prefix":"10.1007","volume":"63","author":[{"given":"Caroline","family":"Morbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham\u00a0WT, Adamson\u00a0PB, Bourge\u00a0RC et\u00a0al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a\u00a0randomised controlled trial. Lancet 377:658\u2013666","journal-title":"Lancet"},{"key":"1286_CR2","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.1943","volume":"22","author":"CE Angermann","year":"2020","unstructured":"Angermann\u00a0CE, Assmus\u00a0B, Anker\u00a0SD et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF). Eur J Heart Fail 22:1891\u20131901","journal-title":"Eur J Heart Fail"},{"key":"1286_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in heart failure with a\u00a0preserved ejection fraction. N\u00a0Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano\u00a0A, Narotsky\u00a0DL, Hamid\u00a0N et\u00a0al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart\u00a0J 38:2879\u20132887","journal-title":"Eur Heart J"},{"key":"1286_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.hfc.2014.04.011","volume":"10","author":"JG Cleland","year":"2014","unstructured":"Cleland\u00a0JG, Pellicori\u00a0P, Dierckx\u00a0R (2014) Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. Heart Fail Clin 10:511\u2013523","journal-title":"Heart Fail Clin"},{"key":"1286_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland\u00a0JGF, Bunting\u00a0KV, Flather\u00a0MD et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart\u00a0J 39:26\u201335","journal-title":"Eur Heart J"},{"key":"1286_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-med-041316-090654","volume":"69","author":"JD Gladden","year":"2018","unstructured":"Gladden\u00a0JD, Chaanine\u00a0AH, Redfield\u00a0MM (2018) Heart failure with preserved ejection fraction. Annu Rev Med 69:65\u201379","journal-title":"Annu Rev Med"},{"key":"1286_CR8","first-page":"159","volume":"117","author":"S Ihne","year":"2020","unstructured":"Ihne\u00a0S, Morbach\u00a0C, Sommer\u00a0C et al (2020) Amyloidosis-the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int 117:159\u2013166","journal-title":"Dtsch Arztebl Int"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jchf.2015.01.009","volume":"3","author":"DW Kitzman","year":"2015","unstructured":"Kitzman\u00a0DW, Upadhya\u00a0B, Reeves\u00a0G (2015) Hospitalizations and prognosis in elderly patients with heart failure and preserved ejection fraction: time to treat the whole patient. JACC Heart Fail 3:442\u2013444","journal-title":"JACC Heart Fail"},{"key":"1286_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche\u00a0NF, Brachmann\u00a0J, Andresen\u00a0D et\u00a0al (2018) Catheter ablation for atrial fibrillation with heart failure. N\u00a0Engl J Med 378:417\u2013427","journal-title":"N Engl J Med"},{"key":"1286_CR11","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 42:3599\u20133726","journal-title":"Eur Heart J"},{"key":"1286_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"1286_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/eurheartj\/ehaa071","volume":"41","author":"J Motiejunaite","year":"2020","unstructured":"Motiejunaite\u00a0J, Akiyama\u00a0E, Cohen-Solal\u00a0A et al (2020) The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. Eur Heart\u00a0J 41:1357\u20131364","journal-title":"Eur Heart J"},{"key":"1286_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","volume":"289","author":"E Muchtar","year":"2021","unstructured":"Muchtar\u00a0E, Dispenzieri\u00a0A, Magen\u00a0H et\u00a0al (2021) Systemic amyloidosis from A (AA) to T (ATTR): a\u00a0review. J\u00a0Intern Med 289:268\u2013292","journal-title":"J Intern Med"},{"key":"1286_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","volume":"22","author":"C Nitsche","year":"2020","unstructured":"Nitsche\u00a0C, Aschauer\u00a0S, Kammerlander\u00a0AA et al (2020) Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail 22:1852\u20131862","journal-title":"Eur J Heart Fail"},{"key":"1286_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11897-018-0382-z","volume":"15","author":"W Omar","year":"2018","unstructured":"Omar\u00a0W, Pandey\u00a0A, Haykowsky\u00a0MJ et\u00a0al (2018) The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure. Curr Heart Fail Rep 15:75\u201380","journal-title":"Curr Heart Fail Rep"},{"key":"1286_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2019.0693","volume":"321","author":"DL Packer","year":"2019","unstructured":"Packer\u00a0DL, Mark\u00a0DB, Robb\u00a0RA et\u00a0al (2019) Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321:1261\u20131274","journal-title":"JAMA"},{"key":"1286_CR18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl J Med 383:1413\u20131424","journal-title":"N Engl J Med"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer\u00a0M, Butler\u00a0J, Zannad\u00a0F et al (2021) Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation 144:1284\u20131294","journal-title":"Circulation"},{"key":"1286_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.121.056657","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer\u00a0M, Zannad\u00a0F, Anker\u00a0SD (2021) Heart failure and a\u00a0preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-preserved trials. Circulation 144:1193\u20131195","journal-title":"Circulation"},{"key":"1286_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jchf.2018.09.006","volume":"6","author":"A Pandey","year":"2018","unstructured":"Pandey\u00a0A, Patel\u00a0KV, Vaduganathan\u00a0M et\u00a0al (2018) Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. JACC Heart Fail 6:975\u2013982","journal-title":"JACC Heart Fail"},{"key":"1286_CR22","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske\u00a0B, Tschope\u00a0C, de Boer\u00a0RA et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a\u00a0consensus recommendation from the heart failure association (HFA) of the European society of cardiology (ESC). Eur Heart\u00a0J 40:3297\u20133317","journal-title":"Eur Heart J"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt\u00a0B, Pfeffer\u00a0MA, Assmann\u00a0SF et\u00a0al (2014) Spironolactone for heart failure with preserved ejection fraction. N\u00a0Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart\u00a0J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"1286_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy\u00a0YNV, Carter\u00a0RE, Obokata\u00a0M et al (2018) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138:861\u2013870","journal-title":"Circulation"},{"key":"1286_CR26","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg\u00a0FL, Grogan\u00a0M, Hanna\u00a0M et al (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J\u00a0Am Coll Cardiol 73:2872\u20132891","journal-title":"J Am Coll Cardiol"},{"key":"1286_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","volume":"8","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj\u00a0S, Myhre\u00a0PL, Vaduganathan\u00a0M et\u00a0al (2020) Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail 8:640\u2013653","journal-title":"JACC Heart Fail"},{"key":"1286_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","volume":"3","author":"SJ Shah","year":"2018","unstructured":"Shah\u00a0SJ, Feldman\u00a0T, Ricciardi\u00a0MJ et al (2018) One-year safety and clinical outcomes of a\u00a0transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol 3:968\u2013977","journal-title":"JAMA Cardiol"},{"key":"1286_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/eurjhf\/hfs097","volume":"14","author":"MD Smit","year":"2012","unstructured":"Smit\u00a0MD, Moes\u00a0ML, Maass\u00a0AH et\u00a0al (2012) The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail 14:1030\u20131040","journal-title":"Eur J Heart Fail"},{"key":"1286_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon\u00a0SD, Claggett\u00a0B, Lewis\u00a0EF et\u00a0al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart\u00a0J 37:455\u2013462","journal-title":"Eur Heart J"},{"key":"1286_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon\u00a0SD, Vaduganathan\u00a0M et\u00a0al (2020) Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141:352\u2013361","journal-title":"Circulation"},{"issue":"11","key":"1286_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00392-017-1137-7","volume":"106","author":"S St\u00f6rk","year":"2017","unstructured":"St\u00f6rk\u00a0S, Handrock\u00a0R, Jacob\u00a0J, Walker\u00a0J, Calado\u00a0F, Lahoz\u00a0R, Hupfer\u00a0S, Klebs\u00a0S (2017) Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol 106(11):913\u2013922. https:\/\/doi.org\/10.1007\/s00392-017-1137-7. Epub 2017 Jul 26","journal-title":"Clin Res Cardiol"},{"key":"1286_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","volume":"6","author":"CW Tsao","year":"2018","unstructured":"Tsao\u00a0CW, Lyass\u00a0A, Enserro\u00a0D et\u00a0al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6:678\u2013685","journal-title":"JACC Heart Fail"},{"key":"1286_CR34","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s13300-020-00889-9","volume":"11","author":"DM Williams","year":"2020","unstructured":"Williams\u00a0DM, Evans\u00a0M (2020) Are SGLT\u20112 inhibitors the future of heart failure treatment? The EMPEROR-preserved and EMPEROR-reduced trials. Diabetes Ther 11:1925\u20131934","journal-title":"Diabetes Ther"},{"key":"1286_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, Raz\u00a0I, Bonaca\u00a0MP et\u00a0al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med 380:347\u2013357","journal-title":"N Engl J Med"},{"key":"1286_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf\u00a0S, Pfeffer\u00a0MA, Swedberg\u00a0K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"key":"1286_CR37","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, Wanner\u00a0C, Lachin\u00a0JM et\u00a0al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"1286_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","volume":"398","author":"J Lindenfeld","year":"2021","unstructured":"Lindenfeld\u00a0J, Zile\u00a0MR, Desai\u00a0AS et al (2021) Haemodynamic-guided management of heart failure (GUIDE-HF): a\u00a0randomised controlled trial. Lancet 398:991\u20131001","journal-title":"Lancet"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01286-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T14:05:31Z","timestamp":1656511531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01286-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01286-z","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"1 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Morbach: 1)\u00a0Forschungskooperation mit Universit\u00e4t W\u00fcrzburg und Tomtec Imaging Systems gef\u00f6rdert im Rahmen des Masterplans Bayern digital\u00a0II; 2)\u00a0\u201espeakers bureau\/travel grant\/advisory board\/patient eligibility board\u201c von Amgen, Tomtec, Orion Pharma, Alnylam, Akcea, Sobi, Pfizer, Boehringer Ingelheim und EBR Systems; 3)\u00a0\u201eprincipal investigator\u201c in Studien von Alnylam, AstraZeneca und Bayer; 4)\u00a0F\u00f6rderung durch das Interdisziplin\u00e4re Zentrum f\u00fcr Klinische Forschung\u00a0\u2013 IZKF W\u00fcrzburg (Advanced Clinician-Scientist Programm). C.\u00a0Wanner: 1)\u00a0Sprecher oder \u201eadvisor\u201c f\u00fcr bzw. Studienleiter in Studien von AstraZeneca, Bayer, Boehringer Ingelheim, FMC, Gilead, GSK,\u00a0Lilly,\u00a0MSD, Novartis, Sanofi und Vifor. S.\u00a0St\u00f6rk: 1)\u00a0Bundesministerium f\u00fcr Bildung und Forschung (BMBF) #01EO1004 und #01EO1504; Gemeinsamer Bundesausschuss: Erprobungsstudie zum Telemonitoring mittels pulmonalarteriellen Drucksensors. 2)\u00a0Sprecher oder \u201eadvisor\u201c f\u00fcr bzw. Studienleiter in Studien von Akcea, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, IONIS, MSD, Novartis, Orion Pharma, Pfizer, Sanofi, Servier, Sobi und Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}